PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer

BACKGROUND: An increasing amount of evidence has demonstrated that combined or multiple targeted therapies could bring about more durable clinical outcomes, and it is known that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance is related to bypass activation. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ziyi, Zeng, Liang, Zhang, Miaomiao, Zhang, Yongchang, Yang, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186747/
https://www.ncbi.nlm.nih.gov/pubmed/32355810
http://dx.doi.org/10.21037/atm.2020.02.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186747/
https://www.ncbi.nlm.nih.gov/pubmed/32355810
http://dx.doi.org/10.21037/atm.2020.02.43

Ejemplares similares